To determine the impact of tapentadol extended release (ER) versus placebo or oxycodone controlled release (CR) on the work productivity of adults with chronic moderate to severe knee osteoarthritis pain.
Using clinical trial data on pain outcomes, a validated methodology imputed treatment group differences in at-work productivity and associated differences in productivity costs (assuming a $100,000 annual salary per participant).
Imputed improvements in at-work productivity were significantly greater for tapentadol ER compared with either placebo (mean, 1.96% vs 1.51%; P = 0.001) or oxycodone CR (mean, 1.96% vs 1.40%; P < 0.001). Mean net savings per participant were $450 (P < 0.01) for tapentadol ER versus placebo and $560 (P = 0.001) for tapentadol ER versus oxycodone CR.
Effective osteoarthritis pain treatment also may help employees to function better at work and reduce their employers' productivity costs.
From the Program on Health, Work and Productivity (Drs Lerner, Chang, and Rogers), Institute for Clinical Research and Health Policy Studies (Drs Lerner, Chang, and Rogers), Tufts Medical Center, Tufts University School of Medicine, Boston, MA; Sackler Graduate School of Biomedical Sciences (Drs Lerner, Chang, and Rogers), Boston, MA; and Janssen Scientific Affairs, LLC (Mr Benson and Drs Chow, Kim, and Biondi).
Address correspondence to: Debra Lerner, MS, PhD, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St, Box 345, Boston, MA 02111 (firstname.lastname@example.org).
Authors Benson, Chow, Kim, and Biondi are employees of Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson and Johnson. This study was sponsored by Janssen Scientific Affairs, LLC.
Authors Lerner, Chang, Rogers, Benson, Chow, Kim, and Biondi have no relationships/conditions/circumstances that present potential conflict of interest.
The JOEM Editorial Board and planners have no financial interest related to this research.